比较不同血管内血运重建术治疗慢性肢体威胁性缺血所致腹股沟下外周动脉疾病疗效的随机对照试验网络荟萃分析
本研究采用网络荟萃分析比较不同血管内血运重建术治疗慢性肢体威胁性缺血(CLTI)的疗效,检索PubMed和Cochrane对照试验中心注册库(2023年3月14日)。共纳入2655例受试者(94.8%为CLTI),结果显示与普通球囊血管成形术(PBA)相比,药物涂层球囊(DCB)、裸金属支架(BMS)、药物涂层支架(DCS)或斑块旋切术均未显著降低大截肢或死亡风险,作者认为需要更大规模的比较性随机对照试验。
要点
- 与PBA相比,DCB、BMS、DCS或斑块旋切术均未显著降低大截肢或死亡风险。
- DCB改善大截肢结局的GRADE证据确定性为中等,斑块旋切术和BMS为低,DCS为极低。
- 作者认为目前缺乏可靠证据判定BMS、DCB、DCS或斑块旋切术优于PBA,需要更大规模的比较性随机对照试验。
核心结论
- 目前没有随机对照试验证据能可靠地得出BMS、DCB、DCS或斑块旋切术在预防CLTI患者大截肢和死亡方面优于PBA的结论。
- 需要更大规模的比较性随机对照试验来确定最佳的血管内血运重建策略。
研究设计与样本
- 本研究为网络荟萃分析,按照PRISMA指南执行,检索PubMed和Cochrane对照试验中心注册库,检索日期为2023年3月14日。
- 共纳入2655例受试者,其中94.8%患有CLTI。
- 纳入的试验比较了PBA与DCB(11项试验,n=1771)、BMS与DCS(5项试验,n=466)、斑块旋切术与DCB(3项试验,n=194)、PBA与BMS(2项试验,n=70)、PBA与斑块旋切术(1项试验,n=50)以及BMS与DCB(1项试验,n=104)。
- 采用随机效应模型,结果以累积排序曲线下面积图(SUCRA)和森林图呈现,p值≤0.050视为有统计学意义,使用Cochrane协作工具评估偏倚风险。
主要发现
- 与PBA相比,没有任何血运重建策略显著降低大截肢或死亡风险。
- 与PBA相比,DCB改善大截肢结局的GRADE证据确定性为中等,斑块旋切术和BMS为低,DCS为极低。
- 偏倚风险评估显示,16项试验为低风险,6项试验为有些担忧,1项试验为高风险。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出目前缺乏随机对照试验证据来可靠地判定BMS、DCB、DCS或斑块旋切术优于PBA。
- 作者指出需要更大规模的比较性随机对照试验来确定最佳的血管内血运重建策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to compare the efficacy of different endovascular revascularisation procedures for treating chronic limb threatening ischaemia (CLTI) using network meta-analysis (NMA). DATA SOURCES: The databases PubMed and Cochrane Central Register for Controlled Trials were searched on 14 March 2023. REVIEW METHODS: A NMA of randomised controlled trials (RCTs) reporting the efficacy of different endovascular revascularisation techniques for treating CLTI was performed according to PRISMA guidelines. The primary and secondary outcomes were major amputation and death, respectively. Random effects models were developed and the results were presented using surface under the cumulative ranking curve plots and forest plots. A p value of ≤ .050 was considered statistically significant. The Cochrane collaborative tool was used to assess risk of bias. RESULTS: A total of 2 655 participants of whom 94.8% had CLTI were included. Eleven trials compared plain balloon angioplasty (PBA) vs. drug coated balloon (DCB) angioplasty (n = 1 771), five trials compared bare metal stent (BMS) vs. drug coated stent (DCS) (n = 466), three trials compared atherectomy vs. DCB (n = 194), two trials compared PBA vs. BMS (n = 70), one trial compared PBA vs. atherectomy (n = 50), and one trial compared BMS vs. DCB (n = 104). None of the revascularisation strategies significantly reduced the risk of major amputation or death compared with PBA. Using the network estimates, GRADE certainty of evidence for improvement in major amputation outcomes for DCB was moderate, for atherectomy and BMS was low, and for DCS was very low compared with PBA. Risk of bias was low in 16 trials, of some concerns in six trials, and high in one trial, respectively. CONCLUSION: There is no current evidence from RCTs to reliably conclude that BMS, DCB, DCS, or atherectomy are superior to PBA in preventing major amputation and death in patients with CLTI. Larger comparative RCTs are needed to identify the best endovascular revascularisation strategy.
引用
- Thanigaimani S, Sun D, Ahmad U, et al. Network Meta-analysis of Randomised Controlled Trials Comparing the Outcomes of Different Endovascular Revascularisation Treatments for Infra-inguinal Peripheral Arterial Disease Causing Chronic Limb Threatening Ischaemia. Eur J Vasc Endovasc Surg. 2024. PMID: 38754723. doi:10.1016/j.ejvs.2024.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。